ArticleDrug design, development and therapy2026
Association of Sugammadex Exposure with Venous Thrombosis Risk Following Primary Total Knee Arthroplasty: A Multi-Institutional Retrospective Analysis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although sugammadex may facilitate early postoperative mobilization and transiently influence coagulation parameters, its association with venous thromboembolism (VTE) risk after total knee arthroplasty (TKA) remains unclear. Patients and methods: This multi-institutional retrospective study utilized the TriNetX research network to identify individuals aged ≥45 years who received rocuronium and underwent primary TKA between 2010 and 2024. Patients were categorized by reversal agent: sugammadex or neostigmine. The neostigmine group served as the active comparator throughout the study. After 1:1 propensity score matching, 22,844 pairs were analyzed. The primary outcome was VTE incidence at 14 days. Secondary outcomes included deep vein thrombosis (DVT), pulmonary embolism (PE), pneumonia, urinary tract infection (UTI), postoperative nausea/vomiting (PONV), and mortality at 14 and 90 days. Results: Sugammadex use was associated with a significantly lower risk of VTE at 14 days (odds ratio[OR] 0.60, 95%confidence interval [CI] 0.49-0.74, p<0.001; absolute risk difference, -0.41 percentage points), with lower risks observed for both DVT (OR 0.65, p=0.001) and PE (OR 0.58, p=0.001). This association persisted at 90 days (OR 0.72, 95% CI 0.62-0.84, p<0.001; absolute risk difference, -0.50 percentage points). Sugammadex was also associated with lower rates of pneumonia (p=0.018), UTI (p<0.001), and PONV (p=0.005) at 14 days, without significant differences in mortality. Sensitivity and subgroup analyses yielded results consistent with the primary findings. Conclusion: Use of sugammadex was associated with a decreased risk of VTE after primary TKA. Given the observational design and potential for residual confounding, these hypothesis-generating findings warrant confirmation through prospective randomized trials to elucidate the underlying mechanisms and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.